Novartis has expanded its presence in the gene therapy field with the acquisition of Vedere Bio Inc, a US gene therapy company launched in 2019 by Atlas Venture, an early-stage venture capital fund. Vedere has technology for potentially restoring vision in patients whose sight has been impaired by the loss of photoreceptor cells. The technology is based on optogenetics which describes a biological technique for using light to control neurons related to sight.
